Last $252.67 USD
Change Today -0.27 / -0.11%
Volume 1.2M
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Open
$254.32
Previous Close
$252.94
Day High
$254.74
Day Low
$252.08
52 Week High
07/18/14 - $258.55
52 Week Low
07/26/13 - $107.05
Market Cap
49.7B
Average Volume 10 Days
3.4M
EPS TTM
--
Shares Outstanding
196.5M
EX-Date
03/5/14
P/E TM
--
Dividend
$1.02
Dividend Yield
0.24%
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc-adr (SHPG) Key Developments

Shire plc Announces Results from Two Phase IV ADHD studies

Shire plc has announced results from two Phase IV efficacy and safety studies of Vyvanse compared with Concerta with a placebo reference arm in adolescents aged 13-17 diagnosed with attention-deficit/hyperactivity disorder, or ADHD. In SPD489-406, the forced-dose titration study, Vyvanse was found to be statistically superior to Concerta on the primary efficacy analysis (p = 0.0013) with mean reductions on the ADHD RS-IV total score of 25.4 and 22.1 points, respectively. In SPD489-405, the dose optimization study, neither Vyvanse nor Concerta was found to be statistically superior to the other on the primary efficacy analysis (p = 0.0717), with a larger mean improvement found for Vyvanse than Concerta (mean reductions on the ADHD-RS-IV total score of 25.6 and 23.5 points, respectively). The primary efficacy endpoint for both studies was defined as the change from baseline in ADHD-RS-IV total score at Week 6 and Week 8, respectively. In both studies, the types of adverse events appear to be generally consistent with the known safety profile for Vyvanse established in studies of adolescents with ADHD. The Phase IV, randomized, double-blind, multicenter, parallel-group, active-controlled, forced-dose titration efficacy and safety study with a placebo reference arm was designed to evaluate the efficacy of Vyvanse compared with Concerta in adolescents (13-17 years of age) with ADHD based on DSM-IV-TR criteria (N=547 treated patients). The primary efficacy outcome was defined as the change from baseline at Week 6 (Visit 6) in the ADHD-RS-IV total score. Patients were randomized to Vyvanse, Concerta, or placebo, respectively, and treated for 6 weeks to evaluate safety and efficacy, followed by a 1-week safety follow-up period. The doses evaluated in this study were Vyvanse 70mg and Concerta 72mg daily. Baseline ADHD-RS-IV total scores were 37.3, 37.0, and 36.1 for Vyvanse, Concerta, and placebo, respectively. At the end of the study [Week 6 (Visit 6)], patients treated with Vyvanse experienced a mean 25.4 point reduction in ADHD-RS-IV total score compared with a 22.1 point reduction for Concerta, and a 17.0 point reduction for placebo. Vyvanse was found to be statistically superior to Concerta (p = 0.0013) on the primary efficacy analysis, with an improvement of 3.4 points compared to Concerta on the ADHD-RS-IV total score. Safety and tolerability evaluations of Vyvanse and Concerta included treatment-emergent adverse events (TEAEs), vital signs, and weight. Exclusion criteria included a known history of cardiovascular disease, clinically significant ECG, blood pressure exceeding the 90th percentile for age, sex and height, current psychiatric diagnosis and a history of substance abuse or dependence. In this study, 1 patient treated with Vyvanse, 1 patient treated with Concerta, and 1 patient treated with placebo experienced serious adverse events (SAEs). Sixteen (16) patients on Vyvanse, 15 patients on Concerta, and 1 patient on placebo had TEAEs that led to study discontinuation. The most commonly reported (>=5% of patients) TEAEs in patients taking Vyvanse included decreased appetite, headache, weight decreased, insomnia, dry mouth, dizziness, irritability, nausea, and upper abdominal pain. The most commonly reported (> =5% of patients) TEAEs in patients taking Concerta included decreased appetite, headache, insomnia, irritability, weight decreased, dizziness, nausea, and nasopharyngitis. There were no deaths in this study. The Phase IV, randomized, double-blind, multicenter, parallel-group, active-controlled, dose-optimization efficacy and safety study with a placebo reference arm was designed to evaluate the efficacy of Vyvanse compared with Concerta in adolescents (13-17 years of age) with ADHD based on DSM-IV-TR criteria (N=459 treated patients). The primary efficacy outcome was defined as the change from baseline at Week 8 (Visit 8) in the Attention- eficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) total score. Patients were randomized to Vyvanse, Concerta, or placebo, respectively, and treated for 8 weeks to evaluate safety and efficacy, followed by a 1-week safety follow-up period. At the end of the dose optimization period, 8.2%, 27.2%, and 52.2% of treated patients were receiving Vyvanse doses of 30, 50, and 70mg, respectively. At the end of the dose optimization period, 5.4%, 18.5%, 22.3%, and 46.2% of treated patients were receiving Concerta doses of 18, 36, 54, and 72mg, respectively. Baseline ADHD-RS-IV total scores were 36.6, 37.8, and 38.2 for Vyvanse, Concerta, and placebo, respectively. At the end of the study [Week 8 (Visit 8)], patients treated with Vyvanse experienced a mean 25.6 point reduction in ADHD-RS-IV total score compared with a 23.5 point reduction for Concerta, and a 13.4 point reduction for placebo.

Shire plc Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Outlook for the Full Year 2014; Reports Impairment Charges for the Second Quarter Ended June 30, 2014; Declares Dividend for the Six Months Ended June 30, 2014, Payable on October 3, 2014

Shire plc reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net income of $523.1 million or 88.6 cents per share on total revenue of $1,502.1 million as against net income of $258.1 million or 45.3 cents per share on total revenue of $1,252.2 million reported last year. Operating income from continuing operations was at $337.9 million against $390.8 million reported last year. Net cash provided by operating activities at $834.0 million against $258.6 million reported last year. GAAP diluted earnings per ADS were at 265.8 cents against 135.9 cents reported last year. Non GAAP Operating income was at $630.2 million against $479.0 million reported last year. Non GAAP net income from continuing operations was at $525.7 million against $360.1 million reported last year. Non GAAP net income was at $525.7 million against $367.6 million reported last year. Non GAAP diluted earnings per ADS were at 267.3 cents against 188.1 cents reported last year. For the six months period, the company reported net income of $753.5 million or 127.6 cents per share on total revenue of $2,777.7 million as against net income of $322.9 million or 57.5 cents per share on total revenue of $2,306.1 million reported last year. Operating income from continuing operations was at $644.8 million against $752.3 million reported last year. Net cash provided by operating activities at $1,080.1 million against $419.0 million reported last year. GAAP diluted earnings per ADS were at 382.8 cents against 172.5 cents reported last year. Non GAAP Operating income was at $1,221.0 million against $900.4 million reported last year. Non GAAP net income from continuing operations was at $989.7 million against $688.9 million reported last year. Non GAAP net income was at $989.7 million against $688.9 million reported last year. Non GAAP diluted earnings per ADS were at 503.1 cents against 359.4 cents reported last year. Net debt was $920 million at June 30, 2014 against net cash of $2,231 million on December 31, 2013. The company increased its guidance for Non GAAP diluted earnings per ADS to low-to-mid 30% growth for the full year 2014 up from previous guidance of mid-to-high 20% growth. Core effective tax rate on Non GAAP income is now expected to be in the range of 17-19% against previous guidance range of 18-20%. Taken together, the company upgraded Non GAAP diluted earnings per ADS growth for the full year 2014 is now expected to be in the low-to-mid 30% range. The company reported intangible asset impairment charges of $22.0 million for the three months to June 30, 2014. In respect of the six months ended June 30, 2014 the Board resolved to pay an interim dividend of 3.83 cents per Ordinary Share against 3.00 cents per Ordinary Share last year. Dividend payments will be made in Pounds Sterling to holders of Ordinary Shares and in US Dollars to holders of ADSs. A dividend of 11.49 cents per ADS was declared which is an increase of 28% compared to 9.00 cents declared last year. The dividend will be paid on October 3, 2014 to shareholders on the register as at the close of business on September 5, 2014.

AbbVie Inc., Shire plc - M&A Call

To discuss merger agreement between Shire plc and AbbVie Inc

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $252.67 USD -0.27

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $217.45 USD -1.23
Allergan Inc/United States $170.06 USD -0.51
Celgene Corp $87.16 USD +0.97
CSL Ltd A$66.80 AUD -0.55
Valeant Pharmaceuticals International Inc C$133.58 CAD +0.05
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 30.6x
Price/Sales 9.2x
Price/Book 8.1x
Price/Cash Flow 45.3x
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.